About Us

We Build Drugs, Not Companies.™

Stuart Sedlack


Stuart started his career in commercial banking in 1988 specializing in trade and project finance and closed his first deals with firms and organizations in lesser developed countries. In 1993, he entered the biotech/pharma industry as Director, Technology Licensing at the University of Maryland Medical System's licensing office. Then, in 1997, he joined Élan where for six years he was a key member of Elan's corporate investment and licensing group based in New York. As Vice President, Corporate Development, Stuart sourced and negotiated a large number of transactions and co-managed a large biotech and specialty pharma investment fund.

After Élan, Stuart was Global Head, Negotiations for Novartis' Infectious Disease business unit in Basel, Switzerland. Stuart closed a number of transactions which helped Novartis establish their presence in this field. Returning to the US in 2006, Stuart joined Alba Therapeutics as Senior Vice President, Corporate Development and, after a relatively short period and following the out-licensing of the company's lead asset, joined Amarin Pharma in 2007. At Amarin, Stuart was Senior Vice President, Corporate Development and a part of the executive management team that refocused the company from CNS to cardiovascular therapeutics and developed and launched the company's lead product in early 2013. In addition to CNS and cardiovascular partnering activities, he was responsible for strategic and operational initiatives including building and managing a network of contract manufacturing relationships.

Stuart studied economics and finance in college and graduate school earning a BS and MBA at the University of Richmond and Babson College, respectively.